DSS (DSS, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by DSS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Heng Fai Ambrose Chan | Director | Sell | — | — |
| 2026-07-09 | Alset Inc. | 10%+ Owner | J | — | — |
| 2025-09-02 | Heng Fai Ambrose Chan | Director | Sell | — | — |
| 2025-09-02 | Alset Inc. | 10%+ Owner | J | — | — |
| 2025-08-22 | Heng Fai Ambrose Chan | Director | J | — | — |
| 2025-02-10 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2024-12-12 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2024-01-02 | William Wai Leung Wu | Director | Sell | — | — |
| 2024-01-02 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2023-04-18 | Frank D Heuszel | Chief Executive Officer | A | — | — |
| 2022-12-14 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2022-12-13 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2022-07-14 | Heng Fai Ambrose Chan | Director | J | — | — |
| 2022-07-11 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2022-06-21 | William Wai Leung Wu | Director | Buy | — | — |
| 2022-06-14 | William Wai Leung Wu | Director | Buy | — | — |
| 2022-06-01 | Frank D Heuszel | Chief Executive Officer | A | — | — |
| 2022-05-27 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2022-04-19 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2022-03-10 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2021-09-10 | Global BioMedical Pte. Ltd. | — | — | — | — |
| 2021-09-10 | Alset EHome International Inc. | 10%+ Owner | Buy | — | — |
| 2021-06-23 | Heng Fai Ambrose Chan | Director | C | — | — |
| 2021-06-17 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2021-05-27 | Heng Fai Ambrose Chan | Director | C | — | — |
| 2020-10-23 | Global BioMedical Pte. Ltd. | 10%+ Owner | C | — | — |
| 2020-08-25 | Heng Fai Ambrose Chan | Director | J | — | — |
| 2020-03-05 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2020-02-27 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2020-02-21 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2019-11-05 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2019-07-25 | Wah Wai Lo | Director | A | — | — |
| 2019-07-24 | Daniel DelGiorno | Director | A | — | — |
| 2019-07-24 | JOSEPH L. SANDERS | Director | A | — | — |
| 2019-07-24 | Frank D Heuszel | Chief Executive Officer | A | — | — |
| 2019-07-24 | JOHN THATCH | Director | A | — | — |
| 2019-07-24 | Stanley V. Grisham | Director | A | — | — |
| 2019-07-24 | Jason Grady | Chief Operating Officer | A | — | — |
| 2019-07-24 | Heng Fai Ambrose Chan | Director | A | — | — |
| 2019-07-24 | Pamela Avallone | Director | A | — | — |
| 2019-07-24 | Brett L Scott | Director | A | — | — |
| 2019-06-10 | JOSEPH L. SANDERS | Director | Buy | — | — |
| 2019-06-10 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2019-05-21 | JOSEPH L. SANDERS | Director | Buy | — | — |
| 2019-03-26 | Heng Fai Ambrose Chan | Director | C | — | — |
| 2019-03-06 | Daniel DelGiorno | Director | J | — | — |
| 2019-02-20 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2018-12-18 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2018-07-05 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2018-04-16 | ROBERT B FAGENSON | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,034,922 | — |
| — | 10%+ Owner | 1,109,588 | — |
| — | 10%+ Owner | 443,926 | — |
| — | Chief Executive Officer | 65,639 | — |
| — | Director | 1,142 | — |
| — | CEO | 868 | — |
| — | Director | 580 | — |
| — | President | 508 | — |
| — | Chief Executive Officer | 339 | — |
| — | Director | 285 | — |
| — | Chief Operating Officer | 125 | — |
| — | CFO | 108 | — |
| — | Director | 68 | — |
| — | VP, Research & Development | 52 | — |
| — | Director | 51 | — |
| — | Director | 51 | — |
| — | Director | 51 | — |
| — | Chief Operating Officer | 51 | — |
| — | Director | 51 | — |
| — | PRESIDENT, DIGITAL DIVISION | 17 | — |
| — | Director | 12 | — |
| — | Director | 6 | — |
| — | Director | 6 | — |
| — | Director | 2 | — |
| — | Director | 2 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DSS quote page; the site-wide leaderboard is on the insider transactions hub.